BASF plans significant investment in Germany and North America

BASF plans to build a new world-scale plant to produce ibuprofen in Ludwigshafen, Germany. Ibuprofen is an active pharmaceutical ingredient that is used for treating pain, fever, and inflammation. The new plant, is scheduled to come onstream in 2021. "It will be the first world-scale ibuprofen plant in Europe," says Dr. Markus Kamieth, Member of the Board of Executive Directors, BASF SE. With this investment, BASF aims to ensure high supply security for its customers and meet growing global demand. BASF is also expanding its ibuprofen capacities at its production site in Bishop, Texas, to fill current supply gaps for ibuprofen in the market. The expansion will come onstream in early 2018. The company will invest approximately €200 million in both projects. "BASF will be the only supplier with two ibuprofen assets worldwide. This makes us a highly reliable partner for our customers," says Kamieth.

"Both investments show our strong commitment to the pharmaceutical industry and our pharma solutions business," says Dr. Melanie MaasBrunner, President of BASF’s Nutrition & Health business. "They enable us to close supply gaps and efficiently support our customers’ growth plans." BASF has been manufacturing ibuprofen at its FDA-audited, cGMPcertified production site in Bishop for over 20 years. BASF operates an award-winning, eco-efficient production process that ensures the highest product quality levels.